urosphere
News & events
Upcoming AACR Virtual Meeting II
We are pleased to announce that Urosphere will be presenting its unique Patient-Derived Xenograft (PDX) bank of prostate cancers at AACR Virtual Meeting II. Poster #1668. June 22 - 24, 2020 Virtual Meeting II Click to view our abstract and register to see the poster on June, 22nd! https://www.abstractsonline.com/pp8/#!/9045/presentation/4863
Merge of Urosphere and Urolead, creating a center of excellence in preclinical urology.
In December 2019, Urosphere acquired Urolead, a company dedicated to uro-oncology and particularly to the development of Patient-Derived Xenografts (PDX) models for kidney, bladder and prostate cancers. Urolead’s expertise and PDX Biobank strengthens Urosphere’s position by providing a full package of specifically relevant models in oncology, from cells to PDXs. "The acquisition of Urolead is an essential part of our development strategy of offering a full package of drug discovery portfolio...
Urosphere participe à la 7e édition des AFSSI Connexions les 2/3 juillet 2019 à Lyon
Urosphere sera présente sur l’espace village AFSSI les 2 et 3 juillet 2019 à Lyon. N'hésitez pas à venir nous voir sur le stand.
Urosphere/ Urolead and Institut Curie will present their last results at the AACR meeting, Denver: Bladder Cancer: Transforming the Field.
Fruit of a long term collaboration, Urosphere and its affiliate Urolead (Toulouse) and Institut Curie (Paris) will present a fully characterized biobank of PDXs from bladder cancers and its relevant use as a drug discovery platform. The results will be presented in poster session A, on Sunday, May 19th and in plenary session 5, on Monday, May 20th. Title: Establishment of a panel of patient-derived tumor xenograft models recapitulating molecular heterogeneity and drug response of...
Urosphere will be present at the European Association of Urology congress 2019.
Urosphere will present a poster at the EAU congress (from 15 to 19 March 2019). Poster 500:Patard PM et al.,Characterization of bladder organoid cultures from healthy and cancer tissues. It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.
DMS : finalisation d’une étude préclinique sur le traitement des dysfonctions érectiles.
Voir le communiqué de presse
AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st.
Urosphere / Urolead will be represented by Repositive’s CEO Fiona Nielsen at the AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st. Come and meet her at booth 817.
Acquisition of Urolead company.
Urosphere is pleased to announce its acquisition of Urolead company.
Urosphere will be present at the International Continence Society 2017
Urosphere will present an oral communication at ICS (Florence, 12-15 september 2017)
Urosphere will be present at the European Association of Urology congress 2017
Urosphere will present two posters at the 32st annual EAU congress (24-28 March 2017).
Upcoming AACR Virtual Meeting II
We are pleased to announce that Urosphere will be presenting its unique Patient-Derived Xenograft (PDX) bank of prostate cancers at AACR Virtual Meeting II. Poster #1668. June 22 - 24, 2020 Virtual Meeting II Click to view our abstract and register to see the poster on June, 22nd! https://www.abstractsonline.com/pp8/#!/9045/presentation/4863
Urosphere participe à la 7e édition des AFSSI Connexions les 2/3 juillet 2019 à Lyon
Urosphere sera présente sur l’espace village AFSSI les 2 et 3 juillet 2019 à Lyon. N'hésitez pas à venir nous voir sur le stand.
Urosphere/ Urolead and Institut Curie will present their last results at the AACR meeting, Denver: Bladder Cancer: Transforming the Field.
Fruit of a long term collaboration, Urosphere and its affiliate Urolead (Toulouse) and Institut Curie (Paris) will present a fully characterized biobank of PDXs from bladder cancers and its relevant use as a drug discovery platform. The results will be presented in poster session A, on Sunday, May 19th and in plenary session 5, on Monday, May 20th. Title: Establishment of a panel of patient-derived tumor xenograft models recapitulating molecular heterogeneity and drug response of...
Urosphere will be present at the European Association of Urology congress 2019.
Urosphere will present a poster at the EAU congress (from 15 to 19 March 2019). Poster 500:Patard PM et al.,Characterization of bladder organoid cultures from healthy and cancer tissues. It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.
AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st.
Urosphere / Urolead will be represented by Repositive’s CEO Fiona Nielsen at the AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st. Come and meet her at booth 817.
Urosphere will be present at the International Continence Society 2017
Urosphere will present an oral communication at ICS (Florence, 12-15 september 2017)
Urosphere will be present at the European Association of Urology congress 2017
Urosphere will present two posters at the 32st annual EAU congress (24-28 March 2017).
Urosphere will be present at the European Association of Urology congress 2016
UROSPHERE will present two posters at the 31st annual EAU congress (13 March 2016 at 12:45 PM, room 14a)
Urosphere will attend the toulouse oncoweek, to be held in toulouse, france, february 03-05, 2016.
We will have an oral communication on “Optical imaging in preclinical tumour models: helpful or pitfall?”
UROsphere attended to the Association Française des Sciences et Techniques de l’Animal de Laboratoire (AFSTAL) annual meeting, Toulouse, France, from 4 to 6 June 2014.
Dr. Murielle Méen presented an oral communication on Wednesday June 4th entitled: UROsphere, experimental platform for urogenital disorders: Focus on interstitial cystitis.
Urosphere takes parts in MAGenTA, a collaborative research project to develop innovative experimental models and clinical trials dedicated to urogenital diseases.
The MAGenTA project consists into a collaborative work between four SMEs and two academic institutions. The aim is to develop new and innovative predictive experimental models in order to provide pharmaceutical companies and academic research with better tools that should facilitate the validation of gene candidates and discovery of new molecules. MAGenTA also includes two clinical studies which will enable validation of the effectiveness of two therapeutic molecules for urogenital diseases....
Urosphere unveils its new web site
UROsphere is pleased to present its new web site that has been redesigned to offer enhanced functionality to better fit with our clients’ needs: Quick access to our assays, models and expertise A restricted area dedicated to our clients Personalized filter by disease area listing pertinent publications Subscribe to our RSS feed to receive our news updates Feel free to contact us with any questions or comments, we will be happy to assist you.
UROsphere and Vectalys selected by the SISMIP for their research programme « Discovery of new targets for prostatic pathologies»
The 3SI program for Innovation in the Health Sector is a call for innovative projects reserved to SMEs located in Midi-Pyrenees Region. This program is also supported by the Regional Board of OSEO (France's national agency for industrial innovation), the Regional Board for Research and Technology (DRRT), the Cancer-Bio-Health cluster and Midi Pyrénées Innovation (MPI). UROsphere and Vectalys (a company specialized in viral vector production and cell transduction expertises for gene discovery...
Urosphere receives a grant from OSEO Innovation.
UROsphere announces that OSEO Innovation has awarded a grant over a 2-year period to expand its experimental research platform for early stage drug development. The funding will be used to develop innovative in vivo and in vitro models to offer a wider range of assays for genitourinary pathologies. OSEO innovation (France's national agency for industrial innovation) funds innovative, technology-oriented projects for commercialization in France and abroad.
Urosphere targets genitourinary pathologies (FR)
UROsphere cible les pathologies génitourinaires. (Gazette du Laboratoire, Mai 2007) Spécialisée sur le marché de niche des pathologies de l'appareil urinaire, cette jeune entreprise innovante toulousaine développe ses propres molécules et propose des services (études pré-cliniques) à ses clients internationaux. Article
“2007: an important year for Urosphere” (FR)
"2007 sera une année capitale pour UROsphere". (Biotech Finances, 19/02/07) En forte croissance depuis son essaimage, UROsphere doit franchir cette année un cap important. Article
Urosphere developed a new experimental model for prostate enlargment.
"Prostatic enlargment and inflamation" is a well estalished model for BPH in rats.
Urosphere joins SISMIP, a health industry association.
UROsphere s'associe au SISMIP, le groupement des industries de la santé en Midi-Pyrénées.
UROsphere continues to grow. (FR)
UROsphere en pleine croissance. (Actu Labo, 24/01/07) Article
UROsphere develops its two main activities abreast. (La Tribune)
Spécialisée dans les pathologies de l'appareil urinaire, la société toulousaine élabore ses propres médicaments. Elle propose aussi ses services aux "big pharmas" du secteur. (La Tribune, 16/01/07)